The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Johan Lochen, Erik Penser Bank. Phone: +46 8 463 80 00. Erik Penser Bank equity research

Felicia Rittemar, Vator Securities, Phone: +46 8 5333 2737. Vator Securities equity research

  Quarterly Report 2 20/21, March 25, 2021

Dear Shareholders and readers

After advice from the European Medicinal Authority EMA and the US FDA, we are now in the process of initiating a pivotal Phase 3 trial with our therapeutic vaccine Diamyd® for type 1 diabetes. The trial is based on the notion of Precision Medicine, where only individuals that we know beforehand to have a high likelihood of benefitting from the treatment will be enrolled.

The Phase 3 trial is based on the notion of precision medicine, where only individuals that we know beforehand to have a high likelihood of benefitting from the treatment will be enrolled.
Ulf Hannelius, President and CEO

Calendar

  
June 2 − June 5, 2021
ATTD 2021
Advanced Technologies & Treatments for Diabetes virtual conference
June 23, 2021
Quarterly Report III
Quarterly Report 3 2020/2021
October 6, 2021
Year-End Report
Year-End Report 2020/2021
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of March 31, 2021

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 9 241 903 13.36 10.03
Essen-Möller, Anders * 2 556 223 3 923 040 9.37 31.99
Lindkvist, Bertil 6 160 000 8.91 6.68
Nordnet Pension 2 287 481 3.31 2.48
Swedbank Försäkring 723 048 1.05 0.78
Konstruktions o Försäljningsaktiebolag 725 000 1.05 0.79
Arandi Development AB 512 000 0.74 0.56
Relbo AB 475 550 0.69 0.52
Lindberg, Mikael 460 021 0.67 0.50
Schelé, Sven 435 000 0.63 0.47
Remaining shareholders 41 670 530 60.24 45.21
Total 2 556 223 66 613 573 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS